Concepts (88)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Transplantation | 7 | 2022 | 88 | 1.750 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 3 | 2022 | 66 | 0.790 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2018 | 17 | 0.630 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2018 | 20 | 0.630 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2018 | 207 | 0.580 |
Why?
|
| Bronchoscopy | 1 | 2018 | 147 | 0.560 |
Why?
|
| Hepatorenal Syndrome | 1 | 2015 | 16 | 0.530 |
Why?
|
| Arterial Pressure | 1 | 2015 | 46 | 0.520 |
Why?
|
| Vasoconstrictor Agents | 1 | 2015 | 107 | 0.500 |
Why?
|
| Acute Kidney Injury | 1 | 2015 | 232 | 0.430 |
Why?
|
| Cognition Disorders | 1 | 2015 | 342 | 0.420 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2019 | 110 | 0.410 |
Why?
|
| Tissue and Organ Procurement | 2 | 2017 | 164 | 0.230 |
Why?
|
| Graft Rejection | 1 | 2005 | 458 | 0.210 |
Why?
|
| Osteoarthropathy, Secondary Hypertrophic | 1 | 2019 | 3 | 0.170 |
Why?
|
| Periostitis | 1 | 2019 | 4 | 0.170 |
Why?
|
| Voriconazole | 1 | 2019 | 11 | 0.170 |
Why?
|
| Antifungal Agents | 1 | 2019 | 108 | 0.160 |
Why?
|
| Tissue Adhesives | 1 | 2018 | 17 | 0.160 |
Why?
|
| Middle Aged | 7 | 2019 | 21119 | 0.150 |
Why?
|
| Midodrine | 1 | 2015 | 7 | 0.130 |
Why?
|
| Trail Making Test | 1 | 2015 | 7 | 0.130 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2015 | 12 | 0.130 |
Why?
|
| Stroop Test | 1 | 2015 | 3 | 0.130 |
Why?
|
| Octreotide | 1 | 2015 | 21 | 0.130 |
Why?
|
| Verbal Learning | 1 | 2015 | 29 | 0.130 |
Why?
|
| Kidney Function Tests | 1 | 2015 | 114 | 0.130 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2017 | 134 | 0.130 |
Why?
|
| Immunosuppressive Agents | 1 | 2019 | 514 | 0.130 |
Why?
|
| Creatinine | 1 | 2015 | 243 | 0.130 |
Why?
|
| Norepinephrine | 1 | 2015 | 276 | 0.130 |
Why?
|
| End Stage Liver Disease | 1 | 2015 | 60 | 0.120 |
Why?
|
| Humans | 11 | 2022 | 68549 | 0.120 |
Why?
|
| Exercise Test | 1 | 2015 | 242 | 0.120 |
Why?
|
| Male | 7 | 2019 | 37283 | 0.120 |
Why?
|
| Tissue Donors | 1 | 2015 | 195 | 0.110 |
Why?
|
| Neuropsychological Tests | 1 | 2015 | 517 | 0.110 |
Why?
|
| Intensive Care Units | 1 | 2015 | 344 | 0.110 |
Why?
|
| Health Status | 1 | 2015 | 429 | 0.110 |
Why?
|
| Prospective Studies | 2 | 2022 | 3703 | 0.110 |
Why?
|
| Lymphangioleiomyomatosis | 1 | 2012 | 9 | 0.100 |
Why?
|
| Liver Cirrhosis | 1 | 2015 | 301 | 0.100 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2012 | 12 | 0.100 |
Why?
|
| Contraindications | 1 | 2012 | 52 | 0.100 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2012 | 17 | 0.100 |
Why?
|
| Severity of Illness Index | 2 | 2015 | 1851 | 0.100 |
Why?
|
| Cognition | 1 | 2015 | 512 | 0.100 |
Why?
|
| Case-Control Studies | 1 | 2015 | 1549 | 0.100 |
Why?
|
| Waiting Lists | 1 | 2012 | 104 | 0.100 |
Why?
|
| Aged | 3 | 2015 | 14842 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 772 | 0.090 |
Why?
|
| Referral and Consultation | 1 | 2012 | 383 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 2265 | 0.080 |
Why?
|
| Depression | 1 | 2015 | 942 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2324 | 0.080 |
Why?
|
| Patient Selection | 1 | 2012 | 592 | 0.080 |
Why?
|
| Scleroderma, Systemic | 1 | 2012 | 446 | 0.080 |
Why?
|
| Female | 5 | 2019 | 38021 | 0.070 |
Why?
|
| Quality of Life | 1 | 2015 | 1515 | 0.070 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 4843 | 0.070 |
Why?
|
| Lung Diseases | 1 | 2007 | 175 | 0.070 |
Why?
|
| Transplantation, Homologous | 1 | 2005 | 242 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2015 | 7268 | 0.060 |
Why?
|
| Gastroesophageal Reflux | 1 | 2007 | 318 | 0.060 |
Why?
|
| Adult | 4 | 2019 | 21379 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2015 | 7028 | 0.060 |
Why?
|
| Lung | 1 | 2007 | 849 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2022 | 791 | 0.040 |
Why?
|
| Registries | 1 | 2022 | 730 | 0.040 |
Why?
|
| Patient Rights | 1 | 2015 | 11 | 0.030 |
Why?
|
| Cystic Fibrosis | 1 | 2019 | 283 | 0.030 |
Why?
|
| Death | 1 | 2015 | 38 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2015 | 403 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2019 | 1615 | 0.020 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2007 | 15 | 0.020 |
Why?
|
| Forced Expiratory Volume | 1 | 2007 | 87 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2007 | 238 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2007 | 714 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2007 | 618 | 0.020 |
Why?
|
| Esophagus | 1 | 2007 | 303 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2007 | 737 | 0.020 |
Why?
|
| Disease Progression | 1 | 2007 | 1037 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 1465 | 0.010 |
Why?
|
| United States | 1 | 2015 | 7338 | 0.010 |
Why?
|
| Prevalence | 1 | 2007 | 1609 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2007 | 2356 | 0.010 |
Why?
|
| Time Factors | 1 | 2007 | 4655 | 0.010 |
Why?
|
| Risk Factors | 1 | 2007 | 5720 | 0.010 |
Why?
|